Evaluation of efficacy on TP regimen combined with trastuzumab in human epidermal growth factor receptor 2 positive breast cancer
Author(s): YIN Ziyi, ZHANG Tie, QU Gengbao, Department of Breast Surgery, Beijing Tiantan Hospital, Capital Medical University
Pages: 1391-1394
Year: 2019 Issue: 12
Journal: Oncology Progress
Keyword: human epidermal growth factor receptor 2 positive; breast cancer; targeting treatment; efficacy;
Abstract: Objective To investigate the evaluation of efficacy on TP regimen combined with trastuzumab in the treatment of human epidermal growth factor receptor 2(HER2) positive breast cancer. Method 70 cases of patients with HER2 positive breast cancer were divided into observation group and control group, with 35 cases in each. The patients in observation group were administered docetaxel+carboplatin(TP regimen) combined with trastuzumab, the patients in control group were administered TP regimen. The clinical efficacy, levels of tumor markers and occurrence of adverse reactions were compared. Result The overall response rate of observation group was 82.86%, and 54.29% in the control group, with statistically significant difference(P<0.05). Before treatment, the differences of carcinoembryonic antigen(CEA), transforming growth factor-β1(TGF-β1), vascular endothelial growth factor(VEGF) and tumor specific growth factor(TSGF) in two groups were not statistically significant(P>0.05). After treatment, the levels of CEA, TGF-β1,VEGF, TSGF decreased in both groups, and the differences were statistically significant(P<0.05), with significant lower levels of CEA, TGF-β1, VEGF, TSGF in observation group than those in the control group(P<0.01). No significant differences of adverse reactions in two groups were observed(P>0.05). Conclusion Targeting treatment of TP regimen combined with trastuzumab in HER2 positive breast cancer is effective, which can decrease the levels of related serum tumor markers, and the safety is adequate.
Pages: 1391-1394
Year: 2019 Issue: 12
Journal: Oncology Progress
Keyword: human epidermal growth factor receptor 2 positive; breast cancer; targeting treatment; efficacy;
Abstract: Objective To investigate the evaluation of efficacy on TP regimen combined with trastuzumab in the treatment of human epidermal growth factor receptor 2(HER2) positive breast cancer. Method 70 cases of patients with HER2 positive breast cancer were divided into observation group and control group, with 35 cases in each. The patients in observation group were administered docetaxel+carboplatin(TP regimen) combined with trastuzumab, the patients in control group were administered TP regimen. The clinical efficacy, levels of tumor markers and occurrence of adverse reactions were compared. Result The overall response rate of observation group was 82.86%, and 54.29% in the control group, with statistically significant difference(P<0.05). Before treatment, the differences of carcinoembryonic antigen(CEA), transforming growth factor-β1(TGF-β1), vascular endothelial growth factor(VEGF) and tumor specific growth factor(TSGF) in two groups were not statistically significant(P>0.05). After treatment, the levels of CEA, TGF-β1,VEGF, TSGF decreased in both groups, and the differences were statistically significant(P<0.05), with significant lower levels of CEA, TGF-β1, VEGF, TSGF in observation group than those in the control group(P<0.01). No significant differences of adverse reactions in two groups were observed(P>0.05). Conclusion Targeting treatment of TP regimen combined with trastuzumab in HER2 positive breast cancer is effective, which can decrease the levels of related serum tumor markers, and the safety is adequate.
Related Articles